April 25, 2024
Bio
Ildong seeks to bring Alzheimer’s disease drug to Europe
[THE INVESTOR] Ildong Pharmaceutical said on June 28 it plans to initiate clinical trials in Europe for its plant-based Alzheimer’s disease drug candidate once it gets positive results from the ongoing studies here.
ID1201, the candidate substance extracted from Chinaberry, also known as melia azedarach, for curing Alzheimer’s disease, has been undergoing phase 2 clinical study in Korea since 2014.
ID1201, the candidate substance extracted from Chinaberry, also known as melia azedarach, for curing Alzheimer’s disease, has been undergoing phase 2 clinical study in Korea since 2014.
 |
“We can’t provide an exact timeline when the current study will be completed, but if the results meet the endpoint we will do further studies in Europe,” an Ildong official told The Investor.
The drug candidate has been shown to be effective in preventing the development of dementia by promoting the activity of the enzyme called alpha-secretase, which prevents the formation of beta amyloid, the main cause of dementia, according to the company.
Ildong said it registered patent applications for ID1201 in China, European Union and Korea.
The phase 2 clinical trials enrolled some 200 patients with Alzheimer’s disease to confirm the safety and efficacy profile of the drug at 14 health care institutions including Seoul National University Bundang Hospital and Chung-Ang University Hospital.
Currently, some 720,000 people suffer from dementia in Korea.
By Park Han-na (hnpark@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050656_0.jpg)
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050672_0.jpg)
